The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice

Shunsuke Eba, Yasushi Hoshikawa, Takashi Moriguchi, Yoichiro Mitsuishi, Hironori Satoh, Kazuyuki Ishida, Tatsuaki Watanabe, Toru Shimizu, Hiroaki Shimokawa, Yoshinori Okada, Masayuki Yamamoto, Takashi Kondo

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator that activates many antioxidant enzymes. Oxidative stress, which accumulates in diseased lungs associated with pulmonary hypertension (PH), is thought to be responsible for the progression of cardiopulmonary changes. To test whether Nrf2 activation would exert therapeutic efficacy against cardiopulmonary changes in a hypoxiainducedPH model, wild-type (WT) and Nrf2-deficient mice as well as Kelch-like ECH associating protein 1 (Keap1) (negative regulator of Nrf2) knockdown mutant mice were exposed to hypobaric hypoxia for 3 weeks. This chronic hypoxia exacerbated right ventricular systolic pressure, right ventricular hypertrophy (RVH), and pulmonary vascular remodeling in the WT mice. These pathological changes were associated with aberrant accumulation of Tenascin-C, a disease- indicative extracellular glycoprotein. Simultaneous administration of oltipraz, a potent Nrf2 activator, significantly attenuated RVH and pulmonary vascular remodeling and concomitantly ameliorated Tenascin-C accumulation in the hypoxic mice. Hypoxia-exposed Nrf2- deficient mice developed more pronounced RVH than WT mice, whereas hypoxia-exposed Keap1-knockdown mice showed less RVH and pulmonary vascular remodeling than WT mice, underscoring the beneficial potency of Nrf2 activity against PH. We also demonstrated that expression of the Nrf2-regulated antioxidant enzymes was decreased in a patient with chronic obstructive pulmonary disease associated with PH. The decreased antioxidant enzymes may underlie the pathogenesis of cardiopulmonary changes in the patient with chronic obstructive pulmonary disease and PH. The pharmacologically or genetically induced Nrf2 activity clearly decreased RVH and pulmonary vascular remodeling in the hypoxic PH model. The efficacy of oltipraz highlights a promising therapeutic potency of Nrf2 activators for the prevention of PH in patients with hypoxemic lung disease.

Original languageEnglish
Pages (from-to)324-333
Number of pages10
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume49
Issue number2
DOIs
Publication statusPublished - 01-08-2013

Fingerprint

Pulmonary diseases
Tenascin
Right Ventricular Hypertrophy
Antioxidants
Pulmonary Hypertension
Enzymes
Oxidative stress
Lung
Glycoproteins
Proteins
Chemical activation
Chronic Obstructive Pulmonary Disease
Lung Diseases
oltipraz
Hypoxia
Ventricular Pressure
Oxidative Stress
Blood Pressure
Vascular Remodeling
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Clinical Biochemistry
  • Cell Biology

Cite this

Eba, Shunsuke ; Hoshikawa, Yasushi ; Moriguchi, Takashi ; Mitsuishi, Yoichiro ; Satoh, Hironori ; Ishida, Kazuyuki ; Watanabe, Tatsuaki ; Shimizu, Toru ; Shimokawa, Hiroaki ; Okada, Yoshinori ; Yamamoto, Masayuki ; Kondo, Takashi. / The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. In: American Journal of Respiratory Cell and Molecular Biology. 2013 ; Vol. 49, No. 2. pp. 324-333.
@article{ce189c11135542b889d18932f79fcc34,
title = "The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice",
abstract = "Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator that activates many antioxidant enzymes. Oxidative stress, which accumulates in diseased lungs associated with pulmonary hypertension (PH), is thought to be responsible for the progression of cardiopulmonary changes. To test whether Nrf2 activation would exert therapeutic efficacy against cardiopulmonary changes in a hypoxiainducedPH model, wild-type (WT) and Nrf2-deficient mice as well as Kelch-like ECH associating protein 1 (Keap1) (negative regulator of Nrf2) knockdown mutant mice were exposed to hypobaric hypoxia for 3 weeks. This chronic hypoxia exacerbated right ventricular systolic pressure, right ventricular hypertrophy (RVH), and pulmonary vascular remodeling in the WT mice. These pathological changes were associated with aberrant accumulation of Tenascin-C, a disease- indicative extracellular glycoprotein. Simultaneous administration of oltipraz, a potent Nrf2 activator, significantly attenuated RVH and pulmonary vascular remodeling and concomitantly ameliorated Tenascin-C accumulation in the hypoxic mice. Hypoxia-exposed Nrf2- deficient mice developed more pronounced RVH than WT mice, whereas hypoxia-exposed Keap1-knockdown mice showed less RVH and pulmonary vascular remodeling than WT mice, underscoring the beneficial potency of Nrf2 activity against PH. We also demonstrated that expression of the Nrf2-regulated antioxidant enzymes was decreased in a patient with chronic obstructive pulmonary disease associated with PH. The decreased antioxidant enzymes may underlie the pathogenesis of cardiopulmonary changes in the patient with chronic obstructive pulmonary disease and PH. The pharmacologically or genetically induced Nrf2 activity clearly decreased RVH and pulmonary vascular remodeling in the hypoxic PH model. The efficacy of oltipraz highlights a promising therapeutic potency of Nrf2 activators for the prevention of PH in patients with hypoxemic lung disease.",
author = "Shunsuke Eba and Yasushi Hoshikawa and Takashi Moriguchi and Yoichiro Mitsuishi and Hironori Satoh and Kazuyuki Ishida and Tatsuaki Watanabe and Toru Shimizu and Hiroaki Shimokawa and Yoshinori Okada and Masayuki Yamamoto and Takashi Kondo",
year = "2013",
month = "8",
day = "1",
doi = "10.1165/rcmb.2011-0396OC",
language = "English",
volume = "49",
pages = "324--333",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "2",

}

Eba, S, Hoshikawa, Y, Moriguchi, T, Mitsuishi, Y, Satoh, H, Ishida, K, Watanabe, T, Shimizu, T, Shimokawa, H, Okada, Y, Yamamoto, M & Kondo, T 2013, 'The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice', American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 2, pp. 324-333. https://doi.org/10.1165/rcmb.2011-0396OC

The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. / Eba, Shunsuke; Hoshikawa, Yasushi; Moriguchi, Takashi; Mitsuishi, Yoichiro; Satoh, Hironori; Ishida, Kazuyuki; Watanabe, Tatsuaki; Shimizu, Toru; Shimokawa, Hiroaki; Okada, Yoshinori; Yamamoto, Masayuki; Kondo, Takashi.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 49, No. 2, 01.08.2013, p. 324-333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice

AU - Eba, Shunsuke

AU - Hoshikawa, Yasushi

AU - Moriguchi, Takashi

AU - Mitsuishi, Yoichiro

AU - Satoh, Hironori

AU - Ishida, Kazuyuki

AU - Watanabe, Tatsuaki

AU - Shimizu, Toru

AU - Shimokawa, Hiroaki

AU - Okada, Yoshinori

AU - Yamamoto, Masayuki

AU - Kondo, Takashi

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator that activates many antioxidant enzymes. Oxidative stress, which accumulates in diseased lungs associated with pulmonary hypertension (PH), is thought to be responsible for the progression of cardiopulmonary changes. To test whether Nrf2 activation would exert therapeutic efficacy against cardiopulmonary changes in a hypoxiainducedPH model, wild-type (WT) and Nrf2-deficient mice as well as Kelch-like ECH associating protein 1 (Keap1) (negative regulator of Nrf2) knockdown mutant mice were exposed to hypobaric hypoxia for 3 weeks. This chronic hypoxia exacerbated right ventricular systolic pressure, right ventricular hypertrophy (RVH), and pulmonary vascular remodeling in the WT mice. These pathological changes were associated with aberrant accumulation of Tenascin-C, a disease- indicative extracellular glycoprotein. Simultaneous administration of oltipraz, a potent Nrf2 activator, significantly attenuated RVH and pulmonary vascular remodeling and concomitantly ameliorated Tenascin-C accumulation in the hypoxic mice. Hypoxia-exposed Nrf2- deficient mice developed more pronounced RVH than WT mice, whereas hypoxia-exposed Keap1-knockdown mice showed less RVH and pulmonary vascular remodeling than WT mice, underscoring the beneficial potency of Nrf2 activity against PH. We also demonstrated that expression of the Nrf2-regulated antioxidant enzymes was decreased in a patient with chronic obstructive pulmonary disease associated with PH. The decreased antioxidant enzymes may underlie the pathogenesis of cardiopulmonary changes in the patient with chronic obstructive pulmonary disease and PH. The pharmacologically or genetically induced Nrf2 activity clearly decreased RVH and pulmonary vascular remodeling in the hypoxic PH model. The efficacy of oltipraz highlights a promising therapeutic potency of Nrf2 activators for the prevention of PH in patients with hypoxemic lung disease.

AB - Nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulator that activates many antioxidant enzymes. Oxidative stress, which accumulates in diseased lungs associated with pulmonary hypertension (PH), is thought to be responsible for the progression of cardiopulmonary changes. To test whether Nrf2 activation would exert therapeutic efficacy against cardiopulmonary changes in a hypoxiainducedPH model, wild-type (WT) and Nrf2-deficient mice as well as Kelch-like ECH associating protein 1 (Keap1) (negative regulator of Nrf2) knockdown mutant mice were exposed to hypobaric hypoxia for 3 weeks. This chronic hypoxia exacerbated right ventricular systolic pressure, right ventricular hypertrophy (RVH), and pulmonary vascular remodeling in the WT mice. These pathological changes were associated with aberrant accumulation of Tenascin-C, a disease- indicative extracellular glycoprotein. Simultaneous administration of oltipraz, a potent Nrf2 activator, significantly attenuated RVH and pulmonary vascular remodeling and concomitantly ameliorated Tenascin-C accumulation in the hypoxic mice. Hypoxia-exposed Nrf2- deficient mice developed more pronounced RVH than WT mice, whereas hypoxia-exposed Keap1-knockdown mice showed less RVH and pulmonary vascular remodeling than WT mice, underscoring the beneficial potency of Nrf2 activity against PH. We also demonstrated that expression of the Nrf2-regulated antioxidant enzymes was decreased in a patient with chronic obstructive pulmonary disease associated with PH. The decreased antioxidant enzymes may underlie the pathogenesis of cardiopulmonary changes in the patient with chronic obstructive pulmonary disease and PH. The pharmacologically or genetically induced Nrf2 activity clearly decreased RVH and pulmonary vascular remodeling in the hypoxic PH model. The efficacy of oltipraz highlights a promising therapeutic potency of Nrf2 activators for the prevention of PH in patients with hypoxemic lung disease.

UR - http://www.scopus.com/inward/record.url?scp=84883168438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883168438&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2011-0396OC

DO - 10.1165/rcmb.2011-0396OC

M3 - Article

C2 - 23590302

AN - SCOPUS:84883168438

VL - 49

SP - 324

EP - 333

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 2

ER -